Eprex 3000 IU (IV/SC Injection)
3000 IU pre-filled syringe: ৳ 1,950.00 (1 x 6: ৳ 11,700.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Erythropoietin alfa |
| Company | Cilag ag switzerland |
| Also available as |
Therapeutic Class
- Drugs for Haemolytic Hypoplastic & Renal Anemia
Indications
- Treatment of anemia in Chronic Kidney Disease (CKD) patients on dialysis and not on dialysis
- Treatment of anemia due to Zidovudine in HIV-infected patients
- Treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy
- Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery
- Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 gm and gestational age of less than 34 weeks
Description
Recombinant human erythropoietin (EPO) expressed in Chinese hamster ovary cells with a 165 amino acid sequence identical to that of human urinary EPO.
Dosage
- Evaluate iron status before and during treatment
- Monitor hemoglobin levels at least weekly until stable, then at least monthly
- Do not increase the dose more frequently than once every 4 weeks
- For patients on dialysis, initiate treatment when hemoglobin level is less than 10 g/dL
- For patients not on dialysis, consider initiating treatment only when hemoglobin level is less than 10 g/dL
- Starting dose for Zidovudine-treated HIV-infected Patients is 100 units/kg 3 times per week
- Administer Erythropoietin alfa subcutaneously at a dose of 3x250 IU/kg b.w. per week for the prevention of anemia of prematurity
Administration
- Do not shake or freeze the product
- Protect syringe from light
- Inspect visually for particulate matter and discoloration before administration
- Discard unused portions of Erythropoietin alfa
Interaction
Effect of Eprex may be potentiated by the simultaneous therapeutic administration of a haematinic agent such as ferrous sulphate when a deficiency state exists
Contraindications
- Uncontrolled hypertension
- Serious allergic reactions to Erythropoietin alfa
- Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin
Side Effects
- Adverse reactions in 5% of Eprex treated patients in clinical studies include hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, upper respiratory tract infection
- Adverse reactions in Zidovudine-treated HIV-infected Patients include pyrexia, cough, rash, and injection site irritation
- Adverse reactions in Cancer Patients on Chemotherapy include nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, headache, depression, dysphagia, hypokalemia, and thrombosis
- Adverse reactions in Surgery Patients include nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension
- Premature infants may experience a fall in serum ferritin values
Pregnancy & Lactation
- Use in pregnancy only if potential benefit outweighs potential risk to the fetus
- Not recommended in pregnant or lactating surgical patients participating in an autologous blood predonation programme
- Use with caution in nursing women
Overdose Effects
Eprex overdosage can cause hemoglobin levels above the desired level, which should be managed with discontinuation or reduction of Eprex dosage and/or with phlebotomy
Storage Conditions
Store at 2°C to 8°C, do not freeze or shake, store in the original package to protect from light